JN
Johnson & Johnson
JNJ·NYSENew Brunswick NJFounded 1886131,000 employees
Large CappharmaPublicOncologyImmunologyNeurologyCardiology
Platform: Diversified
Market Cap
$380B
All Drugs
14
Clinical Trials
23
Failed / Terminated
3
FDA Approved
1
Stock Price & Catalysts (JNJ)
Loading JNJ stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Zanuderotide | JNJ-5687 | Phase 2/3 | 2 | TIGIT | Endometrial CaIPF | ||
| JNJ-179 | JNJ-179 | Approved | 4 | KRASG12C | DMDSCLC | ||
| JNJ-8168 | JNJ-8168 | Phase 2/3 | 1 | FLT3 | PVBladder Ca | ||
| Niranesiran | JNJ-6413 | Phase 2 | 1 | KIF18A | Wet AMDNSCLC | ||
| Voxaderotide | JNJ-1404 | NDA/BLA | 1 | PI3Kα | SchizophreniaObesity | ||
| Mavutenlimab | JNJ-7489 | Phase 3 | 2 | Cl18.2 | PNHSMA | ||
| JNJ-2735 | JNJ-2735 | Phase 2/3 | 2 | Cl18.2 | RCCGBM | ||
| JNJ-5094 | JNJ-5094 | Phase 2/3 | 2 | GIP-R | CKDHeart Failure | ||
| JNJ-8637 | JNJ-8637 | NDA/BLA | 1 | CD20 | Celiac | ||
| JNJ-7458 | JNJ-7458 | Phase 1/2 | 1 | PD-1 | RCC | ||
| Nirarelsin | JNJ-4333 | Phase 2 | 2 | PRMT5 | CeliacCervical Ca | ||
| Cevizanubrutinib | JNJ-5471 | Preclinical | 1 | FcRn | Wilms | ||
| Riboinavolisib | JNJ-2818 | Phase 2/3 | 2 | GLP-1R | IPF | ||
| JNJ-8232 | JNJ-8232 | NDA/BLA | 1 | MALT1 | NMOSD |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (21)